Otsuka Pharmaceutical Co. Ltd. is moving forward with a slow, measured launch of their first-in-class “digital medicine” for psychiatric conditions after a challenging FDA approval process that the companies say ultimately improved the product's usability.
US FDA announced Nov. 13 that it has approved Abilify MyCite (aripiprazole tablets with sensor), developed with partner Proteus...